The effect of cytokine profiles on the viral response to re-treatment in antiviral-experienced patients with chronic hepatitis C virus infection

Background: There have been few studies on the potential immunological factors associated with viral controls in antiviral-experienced patients on a second round of combination therapy. In this study, we evaluated the level of systemic cytokines and potential impact on combination therapy in both antiviral-naive and -experienced patients chronically infected with hepatitis C virus. Methods: Longitudinal analysis of 27 cytokines and chemokines was performed using the multiplex Biorad 27 plex assay in 37 antiviral-naive and 24 experienced chronically HCV-1b-infected patients during combination therapy with peginterferon-alfa and ribavirin. A group of healthy donors was included as the control (n = 11). Results: Fifty percent of antiviral-experienced chronically HCV-patients could achieve a delayed and slow virologic response after 48 weeks combination therapy, comparing with an early and fast virologic response in antiviral-naive patients. A distinction of immune mediators profiling before and during antiviral therapy between antiviral-naive and -experienced patients was identified, IL-4, IFN-gamma and CCL-3 (MIP-1a) were significantly higher in naive patients than those in experienced patients (P = 0.005, 0.047 and 0.017, respectively) while G-CSF in naive was lower than in experienced patients (P < 0.05). Notably, higher Th1 type cytokine IFN-gamma and lower Th2 type cytokine IL-4 at baseline and week 4 were associated with HCV clearance in naive patients, and a similar trend appeared at week 12 in experienced patients. Conclusions: We found a successful second round therapy in antiviral-experienced patients appears to be associated with the host immune response. Dominant Th1-polar cytokines, especially IFN-gamma, is a potential predictor of viral responsiveness. (C) 2011 Elsevier B.V. All rights reserved.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297427200013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701Pharmacology & PharmacyVirologySCI(E)10ARTICLE2247-2549